| 词条 | NK012 |
| 释义 |
It has completed phase II clinical trials for triple-negative breast cancer and relapsed small cell lung cancer.[3] In 2016, Nippon Kayaku received orphan drug designation for NK012 from the US FDA.[4] This means that if it is approved in the United States, Nippon Kayaku will be entitled to 7 years of market exclusivity. This is intended to incentivize future development, but does not mean the drug has been approved. See also
References1. ^http://www.cancer.gov/drugdictionary/?CdrID=574615 {{antineoplastic-drug-stub}}2. ^{{cite web |url=http://cancerres.aacrjournals.org/content/68/6/1631.abstract |title=Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression |year=2008 |author=Sumitomo|display-authors=etal}} 3. ^http://clinicaltrials.gov/ct2/results?term=NK012 4. ^Nippon Kayaku Announces FDA Orphan Drug Designation to New Polymeric micelle Anti-Cancer Drug NK012 for Small Cell Lung Cancer. (2016). Evaluategroup.com. Retrieved 24 November 2017, from http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=644017 1 : Experimental cancer drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。